Premium
Future developments in interferon therapy
Author(s) -
Boiron M.
Publication year - 1987
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910390709
Subject(s) - interferon , immune system , immunology , biology , cancer research , interferon gamma , immunotherapy , cytotoxic t cell , in vitro , genetics
The antitumour effects of interferons in animals and humans are well known. Despite the fact, however, that the 3 types of human interferon, leukocyte alpha‐interferon, fibroblast beta‐interferon and immune gamma‐interferon are available in large amounts through recombinant DNA technology, the practical applicability of interferon therapy in cancer is still not clear. An initial approach to this problem is to determine the mechanism of action of interferons and to find out why, in certain circumstances, they are inactive. There are various ways in which interferon may control tumours– i.e. antiviral action, inhibition of cell growth, stimulation of cell differentiation, changes in cells modulating the susceptibility to immune rejection, or effects on the host immune systems (natural killer system and cytotoxic proteins). The implications of these data in the use of interferon in cancer therapy need to be evaluated. Both alpha‐ and beta‐interferons may have beneficial effects on growth inhibition and differentiation, but gamma‐interferon is probably more effective in boosting the immune recognition and rejection of tumour cells. A combination of alpha‐ and gamma‐interferon may give the best results in vivo , since they often act synergistically in vitro . The sensitivity of individual tumour cells to the various types of interferon needs to be evaluated by measurement of oncogenes mRNA inhibition, G 0 /G 1 arrest and increase in various H‐La antigens. Finally, the aim of any treatment (antiviral action, tumour regression, prevention of metastasis, decreased tumour growth and increased cell differentiation) should be an important consideration in whether interferon therapy is chosen. A major problem remains in understanding why only a small proportion of patients usually show an objective response to interferon. This could be due to individual differences in their sensitivity to interferon, or because patients benefit from interferon therapy only if they are deficient in interferon or if its synthesis is inhibited.